The role of size and charge for blood-brain barrier permeation of drugs and fatty acids

被引:85
作者
Seelig, Anna [1 ]
机构
[1] Univ Basel, Biozentrum, Basel, Switzerland
关键词
P-glycoprotein; passive influx; stokes; active efflux; membrane packing density;
D O I
10.1007/s12031-007-0055-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The lipid bilayer is the diffusion barrier of biological membranes. Highly protective membranes such as the blood-brain barrier (BBB) are reinforced by ABC transporters such as P-glycoprotein (MDR1, ABCB1) and multidrug resistance associated proteins (MRPs, ABCCs). The transporters bind their substrates in the cytosolic lipid bilayer leaflet before they reach the cytosol and flip them to the outer leaflet. The large majority of drugs targeted to the central nervous system (CNS) are intrinsic substrates of these transporters. Whether an intrinsic substrate can cross the BBB depends on whether passive influx is higher than active efflux. In this paper, we show that passive influx can be estimated quantitatively on the basis of Stokesian diffusion, taking into account the ionization constant and the cross-sectional area of the molecule in its membrane bond conformation, as well as the lateral packing density of the membrane. Active efflux by ABC transporters was measured. The calculated net flux is in excellent agreement with experimental results. The approach is exemplified with several drugs and fatty acid analogs. It shows that compounds with small cross-sectional areas (A(D)< 70 angstrom(2)) and/ or intermediate or low charge exhibit higher passive influx than efflux and, therefore, cross the BBB despite being intrinsic substrates. Large (A(D)< 70 angstrom(2)) or highly charged compounds show higher efflux than influx. They cannot cross the BBB and are, thus, apparent substrates for ABC transporters. The strict size and charge limitation for BBB permeation results from the synergistic interaction between passive influx and active efflux.
引用
收藏
页码:32 / 41
页数:10
相关论文
共 48 条
[41]   Structure-activity relationship of P-glycoprotein substrates and modifiers [J].
Seelig, A ;
Landwojtowicz, E .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 12 (01) :31-40
[42]  
SEELIG A, 2002, MEMBRANE STRUCTURE E, P355
[43]   Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding [J].
Seelig, Anna ;
Gerebtzoff, Gregori .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (05) :733-752
[44]   LIPID CONFORMATION IN MODEL MEMBRANES AND BIOLOGICAL-MEMBRANES [J].
SEELIG, J ;
SEELIG, A .
QUARTERLY REVIEWS OF BIOPHYSICS, 1980, 13 (01) :19-61
[45]   The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases [J].
Thuerauf, Norbert ;
Fromm, Martin Friedrich .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2006, 256 (05) :281-286
[46]   Functional role of P-glycoprotein in limiting intestinal absorption of drugs: Contribution of passive permeability to P-glycoprotein mediated efflux transport [J].
Varma, Manthena V. S. ;
Sateesh, Khandavilli ;
Panchagnula, Ramesh .
MOLECULAR PHARMACEUTICS, 2005, 2 (01) :12-21
[47]   DIRECT DETERMINATION BY H-2-NMR OF THE IONIZATION STATE OF PHOSPHOLIPIDS AND OF A LOCAL-ANESTHETIC AT THE MEMBRANE-SURFACE [J].
WATTS, A ;
POILE, TW .
BIOCHIMICA ET BIOPHYSICA ACTA, 1986, 861 (02) :368-372
[48]   Effect of endotoxin on doxorubicin transport across blood-brain barrier and P-glycoprotein function in mice [J].
Zhao, YL ;
Du, J ;
Kanazawa, H ;
Sugawara, A ;
Takagi, K ;
Kitaichi, K ;
Tatsumi, Y ;
Takagi, K ;
Hasegawa, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 445 (1-2) :115-123